EQS-Adhoc: APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger squeeze-out of the minority shareholders of APONTIS PHARMA AG – merger agreement planned
|
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Squeeze Out Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 Monheim / Rhein, 5 March 2025. Zentiva AG today submitted a formal request to APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) pursuant to Sections 62 para.1 and para. 5 UmwG (German Transformation Act) in conjunction with Sections 327a et seq. AktG (German Stock Corporation Act), according to which a merger agreement is to be concluded between the Company and Zentiva, and the Annual General Meeting of APONTIS PHARMA AG is to resolve on the transfer of the shares of the remaining shareholders (minority shareholders) to Zentiva as the majority shareholder in return for an appropriate cash compensation (so-called squeeze-out under merger law). Zentiva has informed APONTIS PHARMA that it holds approximately 93.83% of the Company’s share capital after deduction of the number of treasury shares of APONTIS PHARMA (170,000 shares) in accordance with Section 62 para. 1 sentence 2 UmwG. As a result, Zentiva is the majority shareholder of APONTIS PHARMA within the meaning of Section 62 (5) UmwG in conjunction with Section 327a (1) AktG. The amount of the appropriate cash compensation that Zentiva will grant to the remaining shareholders of the Company for the transfer of the shares will be announced by Zentiva at a later date. APONTIS PHARMA will provide information about the date of the Annual General Meeting at which a corresponding transfer resolution is to be passed in accordance with the statutory requirements. Zentiva has proposed the commencement of negotiations on a merger agreement between Zentiva and APONTIS PHARMA. Investor Relations CROSS ALLIANCE communication GmbH End of Inside Information
05-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | APONTIS PHARMA AG |
| Rolf-Schwarz-Schütte-Platz 1 | |
| 40789 Monheim am Rhein | |
| Germany | |
| E-mail: | ir@apontis-pharma.de |
| Internet: | https://apontis-pharma.de/ |
| ISIN: | DE000A3CMGM5 |
| WKN: | A3CMGM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2096063 |
| End of Announcement | EQS News Service |
|
|
2096063 05-March-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 40,04 | 39,24 | 51,18 | 55,73 | 36,96 | 48,47 | 56,40 | |
| EBITDA1,2 | -1,72 | 1,00 | 2,36 | 5,57 | -13,28 | 3,48 | 4,44 | |
| EBITDA-Margin3 | -4,30 | 2,55 | 4,61 | 10,00 | -35,93 | 7,18 | 7,87 | |
| EBIT1,4 | -2,29 | -0,66 | 0,62 | 3,77 | -15,16 | 1,24 | 2,40 | |
| EBIT-Margin5 | -5,72 | -1,68 | 1,21 | 6,77 | -41,02 | 2,56 | 4,26 | |
| Net Profit (Loss)1 | -2,39 | -1,18 | -0,75 | 2,69 | -12,68 | 0,75 | 1,45 | |
| Net-Margin6 | -5,97 | -3,01 | -1,47 | 4,83 | -34,31 | 1,55 | 2,57 | |
| Cashflow1,7 | -0,24 | 1,45 | 3,43 | 11,02 | -12,60 | -2,90 | 3,10 | |
| Earnings per share8 | -0,28 | -0,14 | -0,09 | 0,32 | -1,49 | 0,09 | 0,17 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: RSM Ebner Stolz
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Apontis Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3CMGM | DE000A3CMGM5 | AG | 95,63 Mio € | 11.05.2021 | Verkaufen | 9F383VCV+Q2 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 28,85 | 25,63 | 1,13 | 57,69 | 3,08 | -32,97 | 1,97 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 17.05.2024 | 08.05.2024 | 09.08.2024 | 07.11.2024 | 31.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +0,63% | +19,68% | +11,94% | +39,58% | -40,79% |
